Skandinaviska Enskilda Banken Ab (Publ) Janux Therapeutics, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $19.9 Billion
- Q1 2025
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 177,820 shares of JANX stock, worth $4.06 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
177,820
Previous 205,167
13.33%
Holding current value
$4.06 Million
Previous $11 Million
56.29%
% of portfolio
0.02%
Previous 0.05%
Shares
4 transactions
Others Institutions Holding JANX
# of Institutions
190Shares Held
57.9MCall Options Held
626KPut Options Held
155K-
Ra Capital Management, L.P. Boston, MA11.2MShares$255 Million6.27% of portfolio
-
Janus Henderson Group PLC London, X04.6MShares$105 Million0.07% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.65MShares$83.4 Million0.19% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.33MShares$76 Million4.61% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$53.5 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $951M
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...